Modulation of ion channels in pulmonary arterial hypertension

Current Pharmaceutical Design

Volumn 13, Issue 24, 2007, Pages 2443-2455

  Guibert, Christelle ^a,b   Marthan, Roger ^a,b   Savineau, Jean Pierre ^a,b  

^a UNIVERSITÉ DE BORDEAUX   (France)

^b INSERM   (France)

Author keywords

Ion channels; Pathophysiology; Pulmonary artery; Pulmonary hypertension; Remodelling; Therapeutic targets; Vascular smooth muscle; Vasoconstriction

Indexed keywords

ADENOSINE TRIPHOSPHATE SENSITIVE POTASSIUM CHANNEL; AMINOREX; ANOREXIGENIC AGENT; BOSENTAN; CALCIUM ACTIVATED POTASSIUM CHANNEL; CALCIUM CHANNEL; CALCIUM ION; CARBON MONOXIDE; CHLORIDE CHANNEL; DEXFENFLURAMINE; DICHLOROACETIC ACID; DILTIAZEM; FENFLURAMINE; ION CHANNEL; MIBEFRADIL; NICARDIPINE; NIFEDIPINE; NITRENDIPINE; PHENTERMINE; POTASSIUM CHANNEL; POTASSIUM CHANNEL KV1.1; POTASSIUM CHANNEL KV1.2; POTASSIUM CHANNEL KV1.5; PRASTERONE; PRASTERONE SULFATE; SIBUTRAMINE; SILDENAFIL; TRANSIENT RECEPTOR POTENTIAL CHANNEL C; UNINDEXED DRUG; VOLTAGE GATED CALCIUM CHANNEL; ANTIHYPERTENSIVE AGENT;

ANTIHYPERTENSIVE ACTIVITY; APOPTOSIS; ARTERY CONSTRICTION; CALCIUM CELL LEVEL; CELL PROLIFERATION; CLINICAL TRIAL; CYTOTOXICITY; DEATH; DRUG EFFICACY; DRUG MEGADOSE; DRUG METABOLISM; DRUG SENSITIVITY; DRUG TOLERABILITY; EPIDEMIC; HEART LUNG TRANSPLANTATION; HEART RIGHT VENTRICLE FAILURE; HEART RIGHT VENTRICLE HYPERTROPHY; HUMAN; LUNG ARTERY PRESSURE; LUNG VASCULAR RESISTANCE; NONHUMAN; OBESITY; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PULMONARY HYPERTENSION; REVIEW; SMOOTH MUSCLE FIBER; DRUG ANTAGONISM; DRUG POTENTIATION; METABOLISM;

ANTIHYPERTENSIVE AGENTS; HUMANS; HYPERTENSION, PULMONARY; ION CHANNELS;

EID: 34548290425     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161207781368585     Document Type: Review

References (180)

1. Rubin LJ. Primary pulmonary hypertension. N Engl J Med 1997; 336: 111-7.
2. Runo, JR, Loyd JE. Primary pulmonary hypertension. Lancet 2003; 361: 1533-44.
3. Jeffery TK, Morrell NW. Molecular and cellular basis of pulmonary vascular remodeling in pulmonary hypertension. Prog Cardiovasc Dis 2002; 45: 173-202.
4. Naeije R. Pulmonary hypertension and right heart failure in chronic obstructive pulmonary disease. Proc. Am Thorac: Soc 2005; 2: 20-2.
5. Humbert M, Yaici A, Sztrymf B, Montani D. Pulmonary hypertension: From genetics to treatments. Rev Pneumol Clin 2004; 60: 196-201.
6. Barbera JA, Peinado VI, Santos S. Pulmonary hypertension in chronic obstructive pulmonary disease. Eur Respir J 2003; 21: 892-905.
7. Simonneau, G, Galie N, Rubin LJ, Langleberi D, Seeger W, Domenighetti G, et al. Clinical classification of pulmonary hypertension. J Am Coll Cardiol 2004; 43: 5S-12S.
8. MacLean MR, Herve P, Eddahibi S, Adnot S. 5-hydroxytryptamine and the pulmonary circulation: Receptors, transporters and relevance to pulmonary arterial hypertension. Br J Pharmacol 2000; 131: 161-8.
9. Mandegar M, Remillard CV, Yuan JX. Ion channels in pulmonary arterial hypertension. Prog Cardiovasc Dis 2002; 45: 81-114.
10. Welsh CH, Hassell KL, Badesch DB, Kressin DC, Marlar RA. Coagulation and fibrinolytic profiles in patients with severe pulmonary hypertension. Chest 1996; 110: 710-7.
11. Stenmark KR, Mecham RP. Cellular and Molecular mechanisms of pulmonary vascular remodeling. Annu Rev Physiol 1997; 59: 89-144.
12. Dinh-Xuan AT, Higenbottam TW, Clelland CA, Pepke-Zaba J, Cremona G, Butt AY, et al. Impairment of endothelium-dependent pulmonary-artery relaxation in chronic obstructive lung disease. N Engl J Med 1991; 324:1539-47.
13. Yuan JX, Aldinger AM, Juhaszova M, Wang J, Conte JV Jr, Gaine SP, et al. Dysfunctional voltage-gated K+ channels in pulmonary artery smooth muscle cells of patients with primary pulmonary hypertension. Circulation 1998; 98: 1400-6.
14. Yu Y, Fantozzi I, Remillard CV, Landsberg JW, Kunichika N, Platoshyn O, et al. Enhanced expression of transient receptor potential channels in idiopathic pulmonary arterial hypertension. Proc Natl Acad Sci USA 2004; 101: 13861-6.
15. Emery CJ, Bee D, Barer GR. Mechanical properties and reactivity of vessels in isolated perfused lungs of chronically hypoxic rats. Clin Sci (Lond) 1981; 61: 569-80.
16. Raffestin B, Adnot S, Mercadier JJ, Levame M, Due P, Braquet P, et al. Synthesis and secretion of atrial natriuretic factor during chronic hypoxia: A study in the conscious instrumented rat. Clin Sci (Lond) 1990; 78: 597-603.
17. Rabinovitch M, Gamble W, Nadas AS, Miettinen OS, Reid L. Rat pulmonary circulation after chronic hypoxia: Hemodynamic and structural features. Am J Physiol 1979; 236: H818-27.
18. Bonnet S, Hyvelin JM, Bonnet P, Marthan R, Savineau JP. Chronic hypoxia-induced spontaneous and rhythmic contractions in the rat main pulmonary artery. Am J Physiol Lung Cell Mol Physiol 2001; 281: L183-92.
19. Sugita T, Hyers TM, Dauber IM, Wagner WW, McMurtry IF, Reeves JT. Lung vessel leak precedes right ventricular hypertrophy in monocrotaline-treated rats. J Appl Physiol 1983; 54: 371-4.
20. Lalich JL, Johnson WD, Raczniak TJ, Shumaker RC. Fibrin thrombosis in monocrotaline pyrrole-induced cor pulmonale in rats. Arch Pathol Lab Med 1977; 101: 69-73.
21. Meyrick B, Reid L. Development of pulmonary arterial changes in rats fed Crotalaria spectabilis. Am J Pathol 1979; 94: 37-51.
22. Bonnet S, Dubuis E, Vandier C, Martin S, Mardian R, Savineau JP. Reversal of chronic hypoxia-induced alterations in pulmonary artery smooth muscle electromechanical coupling upon air breathing. Cardiovasc Res 2002; 53: 1019-28.
23. Jeffery TK, Wanstall JC. Pulmonary vascular remodeling: A target for therapeutic intervention in pulmonary hypertension. Pharmacol Ther 2001; 92: 1-20.
24. Smirnov SV, Robertson TP, Ward JP, Aaronson PI. Chronic hypoxia is associated with reduced delayed rectifier K+ current in rat pulmonary artery muscle cells. Am J Physiol 1994; 266: H365-70.
25. Platoshyn O, Yu Y, Golovina VA, McDaniel SS, Krick S, Li L, et al. Chronic hypoxia decreases K(V) channel expression and function in pulmonary artery myocytes. Am J Physiol Lung Cell Mol Physiol 2001; 280: L801-12.
26. Karaki H, Ozaki H, Hori M, Mitsui-Saito M, Amano K, Harada K, et al. Calcium movements, distribution, and functions in smooth muscle. Pharmacol Rev 1997; 49: 157-230.
27. Savineau JP, Marthan R. Modulation of the calcium sensitivity of the smooth muscle contractile apparatus: Molecular mechanisms, pharmacological and pathophysiological implications. Fundam Clin Pharmacol 1997; 11: 289-99.
28. Guibert C, Marthan R, Savineau JP. Angiotensin II-induced Ca(2+)-oscillations in vascular myocytes from the rat pulmonary artery. Am J Physiol 1996; 270: L637-42.
29. Guibert C, Pacaud P, Loirand G, Mardian R, Savineau JP. Effect of extracellular ATP on cytosolic Ca2+ concentration in rat pulmonary artery myocytes. Am J Physiol 1996; 271: L450-8.
30. Shimoda LA, Sham JS, Shimoda TH, Sylvester JT. L-type Ca(2+) channels, resting [Ca(2+)](i), and ET-1-induced responses in chronically hypoxic pulmonary myocytes. Am J Physiol Lung Cell Mol Physiol 2000; 279: L884-94.
31. Clapp LH, Gurney AM. Modulation of calcium movements by nitroprusside in isolated vascular smooth muscle cells. Pflugers Arch 1991; 418: 462-70.
32. Salvaterra CG, Goldman WF. Acute hypoxia increases cytosolic calcium in cultured pulmonary arterial myocytes. Am J Physiol 1993; 264: L323-8.
33. McMurtry IF, Davidson AB, Reeves JT, Grover RF. Inhibition of hypoxic pulmonary vasoconstriction by calcium antagonists in isolated rat lungs. Circ Res 1976; 38: 99-104.
34. Nelson MT, Patlak JB, Worley JF, Standen NB. Calcium channels, potassium channels, and voltage dependence of arterial smooth muscle tone. Am J Physiol 1990; 259: C3-18.
35. Parekh AB, Penner R. Store depletion and calcium influx. Physiol Rev 1997; 77: 901-30.
36. Berridge MJ, Lipp P, Boobytan MD. The versatility and universality of calcium signalling. Nat Rev Mol Cell Biol 2000; 1: 11-21.
37. Berridge MJ. The endoplasmic reticulum: A multifunctional signaling organelle. Cell Calcium 2002; 32: 235-49.
38. Janiak R, Wilson SM, Montague S, Hume JR. Heterogeneity of calcium stores and elementary release events in canine pulmonary arterial smooth muscle cells. Am J Physiol Cell Physiol 2001; 280: C22-33.
39. Yuan XJ. Voltage-gated K+ currents regulate resting membrane potential and [Ca2+]i in pulmonary arterial myocytes. Circ Res 1995; 77: 370-8
40. Ratz PH, Berg KM, Urban NH, Miner AS. Regulation of smooth muscle calcium sensitivity: KCl as a calcium-sensitizing stimulus. Am J Physiol Cell Physiol 2005; 288: C769-83.
41. Landsberg JW, Yuan JX. Calcium and TRP channels in pulmonary vascular smooth muscle cell proliferation. News Physiol Sci 2004; 19: 44-50.
42. Means AR. Calcium, calmodulin and cell cycle regulation. FEBS Lett 1994; 347: 1-4.
43. Hardingham GE, Chawla S, Johnson CM, Bading H. Distinct functions of nuclear and cytoplasmic calcium in the control of gene expression. Nature 1997; 385: 260-5.
44. Platoshyn O, Golovina VA, Bailey CL, Limsuwan A, Krick S, Juhaszova M, et al. Sustained membrane depolarization and pulmonary artery smooth muscle cell proliferation. Am J Physiol Cell Physiol 2000; 279: C1540-9.
45. Mogami H, Kojima I. Stimulation of calcium entry is prerequisite for DNA synthesis induced by platelet-derived growth factor in vascular smooth muscle cells. Biochem Biophys Res Commun 1993; 196: 650-8.
46. Short AD, Bian J, Ghosh TK, Waldron RT, Rybak SL, Gill DL. Intracellular Ca2+ pool content is linked to control of cell growth. Proc Natl Acad Sci USA 1993; 90: 4986-90.
47. Cai H, Harrison DG. Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ Res 2000; 87: 840-4.
48. Budhiraja R, Tuder RM, Hassoun PM. Endothelial dysfunction in pulmonary hypertension. Circulation 2004; 109: 159-65.
49. Dorfmuller P, Perros F, Balabanian K, Humbert M. Inflammation in pulmonary arterial hypertension. Eur Respir J 2003; 21: 358-63.
50. Herve P, Humbert M, Sithon O, Parent F, Nunes H, Legal C, et al. Pathobiology of pulmonary hypertension. The role of platelets and thrombosis. Clin Chest Med 2001 ; 22: 451-8.
51. Osipenko ON, Alexander D, MacLean MR, Gurney AM. Influence, of chronic hypoxia on the contributions of non-inactivating and delayed rectifier K currents to the resting potential and tone of rat pulmonary artery smooth muscle. Br J Pharmacol 1998; 124: 1335-7.
52. Doi S, Damron DS, Ogawa K, Tanaka S, Horibe M, Murray PA. K(+) channel inhibition, calcium signaling, and vasomotor tone in canine pulmonary artery smooth muscle. Am J Physiol Lung Cell Mol Physiol 2000; 279: L242-51.
53. Bae YM, Park MK, Lee SH, Ho WK, Eann YE. Contribution of Ca2+-activated K+ channels and non-selective cation channels to membrane potential of pulmonary arterial smooth muscle cells of the rabbit. J Physiol 1999; 514 (Pt 3): 747-58.
54. Clapp LH, Gurney AM. ATP-sensitive K+ channels regulate resting potential of pulmonary arterial smooth muscle cells. Am J Physiol 1992; 262: H916-20.
55. Nelson MT, Quayle JM. Physiological roles and properties of potassium channels in arterial smooth muscle. Am J Physiol 1995; 268: C799-822.
56. Gurney AM, Osipenko ON, MacMillan D, McFarlane KM, Tate RJ, Kempsill FE. Two-pore domain K channel, TASK-1, in pulmonary artery smooth muscle cells. Circ Res 2003; 93: 957-64.
57. Patel AJ, Honore E. Molecular physiology of oxygen-sensitive potassium channels. Eur Respir J 2001; 18: 221-7.
58. Evans AM, Osipenko ON, Gurney AM. Properties of a novel K+ current that is active at resting potential in rabbit pulmonary artery smooth muscle cells. J Physiol 1996; 496(Pt 2): 407-20.
59. Olschewski A, Li Y, Tang B, Hanze J, Eul B, Bohle RM, et al. Impact of TASK-1 in human pulmonary artery smooth muscle cells. Circ Res 2006; 98: 1072-80.
60. Wang J, Juhaszova M, Rubin LJ, Yuan XJ. Hypoxia inhibits gene expression of voltage-gated K+ channel alpha subunits in pulmonary artery smooth muscle cells. J Clin Invest 1997; 100: 2347-53.
61. Patel AJ, Lazdunski M, Honore E. Kv2.1/Kv9.3, a novel ATP-dependent delayed-rectifier K+ channel in oxygen-sensitive pulmonary artery myocytes. EMBO J 1997; 16: 6615-25.
62. Archer SL, Souil E, Dinh-Xuan AT, Schremmer B, Mercier JC, El Yaagoubi A, et al. Molecular identification of the role of voltage-gated K+ channels, Kv1.5 and Kv2.1, in hypoxic pulmonary vasoconstriction and control of resting membrane potential in rat pulmonary artery myocytes. J Clin Invest 1998; 101: 2319-30.
63. Yuan XJ, Wang J, Juhaszova M, Golovina VA, Rubin LJ. Molecular basis and function of voltage-gated K+ channels in pulmonary arterial smooth muscle cells. Am J Physiol 1998; 274: L621-35.
64. Hulme JT, Coppock EA, Felipe A, Martens JR, Tamkun MM. Oxygen sensitivity of cloned voltage-gated K(+) channels expressed in the pulmonary vasculature. Circ Res 1999; 85: 489-97.
65. Hogg DS, Davies AR, McMurray G, Kozlowski RZ. K(V)2.1 channels mediate hypoxic inhibition of I(KV) in native pulmonary arterial smooth muscle cells of the rat. Cardiovasc Res 2002; 55: 349-60.
66. Michelakis ED, McMurtry MS, Wu XC, Dyck JR, Moudgil R, Hopkins TA, et al. Dichloroacetate, a metabolic modulator, prevents and reverses chronic hypoxic pulmonary hypertension in rats: Role of increased expression and activity of voltage-gated potassium channels. Circulation 2002; 105: 244-50.
67. Pozeg ZI, Michelakis ED, McMurtry MS, Thebaud B, Wu XC, Dyck JR, et al. In vivo gene transfer of the O2-sensitive potassium channel Kv1.5 reduces pulmonary hypertension and restores hypoxic pulmonary vasoconstriction in chronically hypoxic rats. Circulation 2003; 107: 2037-44.
68. Rabinovitch M. Elastase and the pathobiology of unexplained pulmonary hypertension. Chest 1998; 114: 213S-224S.
69. Durmowicz AG, Stenmark KR. Mechanisms of structural remodeling in chronic pulmonary hypertension. Pediatr Rev 1999; 20: E91-e102.
70. Yu SP, Choi DW. Ions, cell volume, and apoptosis. Proc Natl Acad Sci USA 2000; 97: 9360-2.
71. Krick S, Platoshyn O, McDaniel SS, Rubin LJ, Yuan JX. Augmented K(+) currents and mitochondrial membrane depolarization in pulmonary artery myocyte apoptosis. Am J Physiol Lung Cell Mol Physiol 2001; 281: L887-94.
72. Zhang S, Fantozzi I, Tigno DD, Yi ES, Platoshyn O, Thistlethwaite PA, et al. Bone morphogenetic proteins induce apoptosis in human pulmonary vascular smooth muscle cells. Am J Physiol Lung Cell Mol Physiol 2003; 285: L740-54.
73. Brevnova EE, Platoshyn O, Zhang S, Yuan JX. Overexpression of human KCNA5 increases IK V and enhances apoptosis. Am J Physiol Cell Physiol 2004; 287: C715-22.
74. Ledoux J, Werner ME, Brayden JE, Nelson MT. Calcium-activated potassium channels and the regulation of vascular tone. Physiology (Bethesda) 2006; 21: 69-78.
75. Bonnet S, Savineau JP, Barillot W, Dubuis E, Vandier C, Bonnet P. Role of Ca(2+)-sensitive K(+) channels in the remission phase of pulmonary hypertension in chronic obstructive pulmonary diseases. Cardiovasc Res 2003; 60: 326-36.
76. Orio P, Rojas P, Ferreira G, Latorre R. New disguises for an old channel: MaxiK channel beta-subunits. News Physiol Sci 2002; 17: 156-61.
77. Toro L, Vaca L, Stefani E. Calcium-activated potassium channels from coronary smooth muscle reconstituted in lipid bilayers. Am J Physiol 1991; 260: H1779-89.
78. Peng W, Hoidal JR, Karwande SV, Farrukh IS. Effect of chronic hypoxia on K+ channels: Regulation in human pulmonary vascular smooth muscle cells. Am J Physiol 1997; 272: C1271-8.
79. Muraki S, Tohse N, Seki S, Nagashima M, Yamada Y, Abe T, et al. Decrease in the Ca2+-activated K+ current of pulmonary arterial smooth muscle in pulmonary hypertension rats. Naunyn Schmiedebergs Arch Pharmacol 2001; 364: 183-92.
80. Olschewski A, Hong Z, Linden BC, Porter VA, Weir EK, Cornfield DN. Contribution of the K(Ca) channel to membrane potential and O2 sensitivity is decreased in an ovine PPHN model. Am J Physiol Lung Cell Mol Physiol 2002; 283: L1103-9.
81. Krick S, Platoshyn O, Sweeney M, Kim H, Yuan JX. Activation of K+ channels induces apoptosis in vascular smooth muscle cells. Am J Physiol Cell Physiol 2001; 280: C970-9.
82. Fujita A, Kurachi Y. Molecular aspects of ATP-sensitive K+ channels in the cardiovascular system and K+ channel openers. Pharmacol Ther 2000; 85: 39-53.
83. Seino S, Miki T. Physiological and pathophysiological roles of ATP-sensitive K+ channels. Prog Biophys Mol Biol 2003; 81: 133-76.
84. Cui Y, Tran S, Tinker A, Clapp LH. The molecular composition of K(ATP) channels in human pulmonary artery smooth muscle cells and their modulation by growth. Am J Respir Cell Mol Biol 2002; 26: 135-43.
85. Ganitkevich V, Isenberg G. Contribution of two types of calcium channels to membrane conductance of single myocytes from guinea-pig coronary artery. J Physiol 1990; 426: 19-42.
86. Akaike N, Kanaide H, Kuga T, Nakamura M, Sadoshima J, Tomoike H. Low-voltage-activated calcium current in rat aorta smooth muscle cells in primary culture. J Physiol 1989; 416: 141-60.
87. Quignard JF, Frapier JM, Harricane MC, Albat B, Nargeot J, Richard S. Voltage-gated calcium channel currents in human coronary myocytes. Regulation by cyclic GMP and nitric oxide. J Clin Invest 1997; 99: 185-93.
88. Rodman DM, Reese K, Harral J, Fouty B, Wu S, West J, et al. Low-voltage-activated (T-type) calcium channels control proliferation of human pulmonary artery myocytes. Circ Res 2005; 96: 864-72.
89. Franco-Obregon A, Lopez-Barneo J. Differential oxygen sensitivity of calcium channels in rabbit smooth muscle cells of conduit and resistance pulmonary arteries. J Physiol 1996; 491 (Pt 2): 511-8.
90. Okabe K, Terada K, Kitamura K, Kuriyama H. Selective and long-lasting inhibitory actions of the dihydropyridine derivative, CV-4093, on calcium currents in smooth muscle cells of the rabbit pulmonary artery. J Pharmacol Exp Ther 1987; 243: 703-10.
91. Franco-Obregon A, Lopez-Barneo J. Low PO2 inhibits calcium channel activity in arterial smooth muscle cells. Am J Physiol 1996; 271: H2290-9.
92. Franco-Obregon A, Urena J, Lopez-Barneo J. Oxygen-sensitive calcium channels in vascular smooth muscle and their possible role in hypoxic arterial relaxation. Proc Natl Acad Sci USA 1995; 92: 4715-9.
93. Urena J, Franco-Obregon A, Lopez-Barneo J. Contrasting effects of hypoxia on cytosolic Ca2+ spikes in conduit and resistance myocytes of the rabbit pulmonary artery. J Physiol 1996; 496 (Pt 1): 103-9.
94. Shimoda LA, Sylvester IT, Sham JS. Mobilization of intracellular Ca(2+) by endothelin-1 in rat intrapulmonary arterial smooth muscle cells. Am J Physiol Lung Cell Mol Physiol 2000; 278: L157-64.
95. Priest RM, Robertson TP, Leach RM, Ward JP. Membrane potential-dependent and -independent vasodilation in small pulmonary arteries from chronically hypoxic rats. J Pharmacol Exp Tber 1998; 285: 975-82.
96. Rich S, Brundage BH. High-dose calcium channel-blocking therapy for primary pulmonary hypertension: Evidence for long-term reduction in pulmonary arterial pressure and regression of right ventricular hypertrophy. Circulation 1987; 76: 135-41.
97. Rich S, Kaufmann E, Levy PS. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med 1992; 327: 76-81.
98. Kuga T, Kobayashi S, Hirakawa Y, Kanaide H, Takeshita A. Cell cycle - dependent expression of L- and T-type Ca2+ currents in rat aortic smooth muscle cells in primary culture. Circ Res 1996; 79: 14-9.
99. Casteels R, Kitamura K, Kuriyama H, Suzuki H. The membrane properties of the smooth muscle cells of the rabbit main pulmonary artery. J Physiol 1977; 271: 41-61.
100. Guibert C, Marthan R, Savineau JP. 5-HT induces an arachidonic acid-sensitive calcium influx in rat small intrapulmonary artery. Am J Physiol Lung Cell Mol Physiol 2004; 286: L1228-36.
101. Shuttleworth TJ, Thompson JL, Mignen O. ARC channels: A novel pathway for receptor-activated calcium entry. Physiology (Bethesda) 2004; 19: 355-61.
102. Yu Y, Sweeney M, Zhang S, Platoshyn O, Landsberg J, Rothman A, et al. PDGF stimulates pulmonary vascular smooth muscle cell proliferation by upregulating TRPC6 expression. Am J Physiol Cell Physiol 2003; 284: C316-30.
103. Gonzalez De La Fuente P, Savineau JP, Marthan R. Control of pulmonary vascular smooth muscle tone by sarcoplasmic reticulum Ca2+ pump blockers: Thapsigargin and cyclopiazonic acid. Pflugers Arch 1995; 429: 617-24.
104. Kunichika N, Yu Y, Remillard CV, Platoshyn O, Zhang S, Yuan JX. Overexpression of TRPC1 enhances pulmonary vasoconstriction induced by capacitative Ca2+ entry. Am J Physiol Lung Cell Mol Physiol 2004; 287: L962-9.
105. McDaniel SS, Platoshyn O, Wang J, Yu Y, Sweeney M, Krick S, et al. Capacitative Ca(2+) entry in agonist-induced pulmonary vasoconstriction. Am J Physiol Lung Cell Mol Physiol 2001; 280: L870-80.
106. Ng LC, Gurney AM. Store-operated channels mediate Ca(2+) influx and contraction in rat pulmonary artery. Circ Res 2001; 89: 923-9.
107. Snetkov VA, Aaronson PI, Ward JP, Knock GA, Robertson TP. Capacitative calcium entry as a pulmonary specific vasoconstrictor mechanism in small muscular arteries of the rat. Br J Pharmacol. 2003; 140: 97-106.
108. Flemming R, Cheong A, Dedman AM, Beech DJ. Discrete store-operated calcium influx into an intracellular compartment in rabbit arteriolar smooth muscle. J Physiol 2002; 543: 455-64.
109. Golovina VA, Platoshyn O, Bailey CL, Wang J, Limsuwan A, Sweeney M, et al. Upregulated TRP and enhanced capacitative Ca(2+) entry in human pulmonary artery myocytes during proliferation. Am J Physiol Heart Circ Physiol 2001; 280: H746-55.
110. Sweeney M, Yu Y, Platoshyn O, Zhang S, McDaniel SS, Yuan JX. Inhibition of endogenous TRP1 decreases capacitative Ca2+ entry and attenuates pulmonary artery smooth muscle cell proliferation. Am J Physiol Lung Cell Mol Physiol 2002; 283: L144-55.
111. Zhang S, Remillard CV, Fantozzi I, Yuan JX. ATP-induced mitogenesis is mediated by cyclic AMP response element-binding protein-enhanced TRPC4 expression and activity in human pulmonary artery smooth muscle cells. Am J Physiol Cell Physiol 2004; 287: C1192-201.
112. Park KS, Lee HA, Earm KH, Ko JH, Earm YE, Kim SJ. Differential Distribution of Mechanosensitive Nonselective Cation Channels in Systemic and Pulmonary Arterial Myocytes of Rabbits. J Vasc Res 2006; 43: 347-354.
113. Clapham DE. TRP channels as cellular sensors. Nature 2003; 426: 517-24.
114. Kunichika N, Landsberg JW, Yu Y, Kunichika H, Thistlethwaite PA, Rubin LJ, et al. Bosentan inhibits transient receptor potential channel expression in pulmonary vascular myocytes. Am J Respir Crit Care Med 2004; 170: 1101-7.
115. Lin MJ, Leung GP, Zhang WM, Yang XR, Yip KP, Tse CM, et al. Chronic hypoxia-induced upregulation of store-operated and receptor-operated Ca2+ channels in pulmonary arterial smooth muscle cells: A novel mechanism of hypoxic pulmonary hypertension. Circ Res 2004; 95: 496-505.
116. Walker RL, Hume JR, Horowitz B. Differential expression and alternative splicing of TRP channel genes in smooth muscles. Am J Physiol Cell Physiol 2001; 280: C1184-92.
117. Wang J, Shimoda LA, Sylvester JT. Capacitative calcium entry and TRPC channel proteins are expressed in rat distal pulmonary arterial smooth muscle. Am J Physiol Lung Cell Mol Physiol 2004; 286: L848-58.
118. Wang J, Weigand L, Lu W, Sylvester JT, Semenza GL, Shimoda LA. Hypoxia Inducible Factor 1 Mediates Hypoxia-Induced TRPC Expression and Elevated Intracellular Ca2+ in Pulmonary Arterial Smooth Muscle Cells. Circ Res 2006; 98:1528-37.
119. Yang XR, Lin MJ, McIntosh LS, Sham JS. Functional expression of transient receptor potential melastatin- and vanilloid-related channels in pulmonary arterial and aortic smooth muscle. Am J Physiol Lung Cell Mol Physiol 2006; 290: L1267-76.
120. Keegan A, Morecroft I, Smillie D, Hicks MN, MacLean MR. Contribution of the 5-HT(1B) receptor to hypoxia-induced pulmonary hypertension: converging evidence using 5-HT(1B)-receptor knockout mice and the 5-HT(1B/1D)-receptor antagonist GR127935. Circ Res 2001; 89:1231-9.
121. MacLean MR, Sweeney G, Baird M, McCulloch KM, Houslay M, Morecroft 1. 5-Hydroxytryptamine receptors mediating vasoconstriction in pulmonary arteries from control and pulmonary hypertensive rats. Br J Pharmacol 1996; 119: 917-30.
122. Jernigan NL, Broughton BR, Walker BR, Resta TC. Impaired NO-dependent inhibition of store- and receptor-operated calcium entry in pulmonary vascular smooth muscle after chronic hypoxia. Am J Physiol Lung Cell Mol Physiol 2006; 290: L517-25.
123. Yuan XJ. Role of calcium-activated chloride current in regulating pulmonary vasomotor tone. Am J Physiol 1997; 272: L959-68.
124. Leblanc N, Ledoux J, Saleh S, Sanguinetti A, Angermann J, O'Driscoll K, et al. Regulation of calcium-activated chloride channels in smooth muscle cells: A complex picture is emerging. Can J Physiol Pharmacol 2005; 83: 541-56.
125. Nakazawa H, Hori M, Murata T, Ozaki H, Karaki H. Contribution of chloride channel activation to the elevated muscular tone of the pulmonary artery in monocrotaline-induced pulmonary hypertensive rats. Jpn J Pharmacol 2001; 86: 310-5.
126. Clapp LH, Turner JL, Kozlowski RZ. Ca(2+)-activated Cl-currents in pulmonary arterial myocytes. Am J Physiol 1996; 270: H1577-84.
127. Smani T, Iwabuchi S, Lopez-Barneo J, Urena J. Differential segmental activation of Ca2+ -dependent Cl-and K+ channels in pulmonary arterial myocytes. Cell Calcium 2001; 29: 369-77.
128. Piper AS, Large WA. Multiple conductance states of single Ca2+- activated Cl- channels in rabbit pulmonary artery smooth muscle cells. J Physiol 2003; 547: 181-96.
129. Guibert C, Marthan R, Savineau JP. Oscillatory Cl- current induced by angiotensin II in rat pulmonary arterial myocytes: Ca2+ dependence and physiological implication. Cell Calcium 1997; 21: 421-9.
130. Hyvelin JM, Guibert C, Marthan R, Savineau JP. Cellular mechanisms and role of endothelin-1-induced calcium oscillations in pulmonary arterial myocytes. Am J Physiol 1998; 275: L269-82.
131. Doughty JM, Langton PD. Measurement of chloride flux associated with the myogenic response in rat cerebral arteries. J Physiol 2001; 534: 753-61.
132. Guan YY, Wang GL, Zhou JG. The ClC-3 Cl(-) channel in cell volume regulation, proliferation and apoptosis in vascular smooth muscle cells. Trends Pharmacol Sci 2006; 27: 290-6.
133. Nilius B, Droogmans G. Amazing chloride channels: An overview. Acta Physiol Scand 2003; 177: 119-47.
134. Xiao GN, Guan YY, He H. Effects of Cl- channel blockers on endothelin-1 -induced proliferation of rat vascular smooth muscle cells. Life Sci 2002; 70: 2233-41.
135. Dai YP, Bongalon S, Hatton WJ, Hume JR, Yamboliev IA. ClC-3 chloride channel is upregulated by hypertrophy and inflaromation in rat and canine pulmonary artery. Br J Pharmacol 2005; 145: 5-14.
136. Lamb FS, Clayton GH, Liu RX, Smith RL, Barna TJ, Schutte BC. Expression of CLCN voltage-gated chloride channel genes in human blood vessels. J Mol Cell Cardiol 1999; 31: 657-66.
137. Wang GX, Hatton WJ, Wang GL, Zhong J, Yamboliev I, Duan D, et al. Functional effects of novel anti-CIC-3 antibodies on native volume-sensitive osmolyte and anion channels in cardiac and smooth muscle cells. Am J Physiol Heart Circ Physiol 2003; 285: H1453-63.
138. Yamazaki J, Duan D, Janiak R, Kuenzli K, Horowitz B, Hume JR. Functional and molecular expression of volume-regulated chloride channels in canine vascular smooth muscle cells. J Physiol 1998; 507 (Pt 3): 729-36.
139. Day RM, Agyeman AS, Segel MJ, Chevere RD, Angelosanto JM, Suzuki YJ, et al. Serotonin induces pulmonary artery smooth muscle cell migration. Biochem Pharmacol 2006; 71: 386-97.
140. Lee SL, Fanburg BL. Serotonin produces a configurational change of cultured smooth muscle cells that is associated with elevation of intracellular cAMP. J Cell Physiol 1992; 150: 396-405.
141. Oriowo MA. Chloride channels and alpha1-adrenoceptor-mediated pulmonary artery smooth muscle contraction: Effect of pulmonary hypertension. Eur J Pharmacol 2004; 506: 157-63.
142. Farrukh IS, Peng W, Orlinska U, Hoidal JR. Effect of dehydroepiandrosterone on hypoxic pulmonary vasoconstriction: A Ca(2+)-activated K(+)-channel opener. Am J Physiol 1998; 274: L186-95.
143. Peng W, Hoidal JR, Farrukh IS. Role of a novel KCa opener in regulating K+ channels of hypoxic human pulmonary vascular cells. Am J Respir Cell Mol Biol 1999; 20: 737-45.
144. Hampl V, Bibova J, Povysilova V, Herget J. dehydroepiandrosterone sulphate reduces chronic hypoxic pulmonary hypertension in rats. Eur Respir J 2003; 21: 862-5.
145. Bonnet S, Dumas-de-La-Roque E, Begueret H, Marthan R, Fayon M, Dos Santos P, et al. Dehydroepiandrosterone (DHEA) prevents and reverses chronic hypoxic pulmonary hypertension. Proc Natl Acad Sci USA 2003; 100: 9488-93.
146. Ballard SA, Gingell CJ, Tang K, Turner LA, Price ME, Naylor AM. Effects of sildenafil on the relaxation of human corpus cavernosum tissue in vitro and on the activities of cyclic nucleotide phosphodiesterase isozymes. J Urol 1998; 159: 2164-71.
147. Moreland RB, Goldstein I, Traish A. Sildenafil, a novel inhibitor of phosphodiesterase type 5 in human corpus cavernosum smooth muscle cells. Life Sci 1998; 62: PL 309-18.
148. Jeremy JY, Ballard SA, Naylon AM, Miller MA, Angelini GD. Effects of sildenafil, a type-5 cGMP phosphodiesterase inhibitor, and papaverine on cyclic GMP and cyclic AMP levels in the rabbit corpus cavernosum in vitro. Br J Urol 1997; 79: 958-63.
149. Boolell M, Gepi-Attee S, Gingell JC, Allen MJ. Sildenafil, a novel effective oral therapy for male erectile dysfunction. Br J Urol 1996; 78: 257-61.
150. Maclean MR, Johnston ED, McCulloch KM, Pooley L, Houslay MD, Sweeney G. Phosphodiesterase isoforms in the pulmonary arterial circulation of the rat: Changes in pulmonary hypertension. J Pharmacol Exp Ther 1997; 283: 619-24.
151. Pauvert O, Salvail D, Rousseau E, Lugnier C, Marthan R, Savineau JP. Characterisation of cyclic nucleotide phosphodiesterase isoforms in the media layer of the main pulmonary artery. Biochem Pharmacol 2002; 63: 1763-72.
152. Sebkhi A, Strange JW, Phillips SC, Wharton J, Wilkins MR. Phosphodiesterase type 5 as a target for the treatment of hypoxia-induced pulmonary hypertension. Circulation 2003; 107: 3230-5.
153. Pauvert O, Lugnier C, Keravis T, Marthan R, Rousseau E, Savineau JP. Effect of sildenafil on cyclic nucleotide phosphodiesterase activity, vascular tone and calcium signaling in rat pulmonary artery. Br J Pharmacol 2003; 139: 513-22.
154. Rabe KF, Tenor H, Dent G, Schudt C, Nakashima M, Magnussen H. Identification of PDE isozymes in human pulmonary artery and effect of selective PDE inhibitors. Am J Physiol 1994; 266: L536-43.
155. Michelakis ED, Tymchak W, Noga M, Webster L, Wu XC, Lien D, et al. Long-term treatment with oral sildenafil is safe and improves functional capacity and hemodynamics in patients with pulmonary arterial hypertension. Circulation 2003; 109: 2066-9.
156. Pauvert O, Bonnet S, Rousseau E, Marthan R, Savineau JP. Sildenafil alters calcium signaling and vascular tone in pulmonary arteries from chronically hypoxic rats. Am J Physiol Lung Cell Mol Physiol 2004; 287: L577-83.
157. Schermuly RT, Kreisselmeier KP, Ghofrani HA, Yilmaz H, Butrous G, Ermert L, et al. Chronic sildenafil treatment inhibits monocrotaline-induced pulmonary hypertension in rats. Am J Respir Crit Care Med 2004; 169: 39-45.
158. Madden BP, Allenby M, Loke TK Sheth A. A potential role for sildenafil in the management of pulmonary hypertension in patients with parenchymal lung disease. Vascul Pharmacol 2006; 44: 372-6.
159. Singh TP, Rohit M, Grover A, Malhotra S, Vijayvergiya R. A randomized, placebo-controlled, double-blind, crossover study to evaluate the efficacy of oral sildenafil therapy in severe pulmonary artery hypertension. Am Heart J 2006; 151: 851 e1-5.
160. Stanford SJ, Walters MJ, Hislop AA, Haworth SG, Evans TW, Mann BE, et al. Heme oxygenase is expressed in human pulmonary artery smooth muscle where carbon monoxide has an anti-proliferative role. Eur J Pharmacol 2003; 473: 135-41.
161. Carraway MS, Ghio AJ, Carter JD, Piantadosi CA. Expression of heme oxygenase-1 in the lung in chronic hypoxia. Am J Physiol Lung Cell Mol Physiol 2000; 278: L806-12.
162. Christou H, Morita T, Hsieh CM, Koike H, Arkonac B, Perrella MA, et al. Prevention of hypoxia-induced pulmonary hypertension by enhancement of endogenous heme oxygenase-1 in the rat. Circ Res 2000; 86: 1224-9.
163. Minamino T, Christou H, Hsieh CM, Liu Y, Dhawan V, Abraham NG, et al. Targeted expression of heme oxygenase-1 prevents the pulmonary inflammatory and vascular responses to hypoxia. Proc Natl Acad Sci USA 2001; 98: 8798-803.
164. Swenson ER. Carbonic anhydrase inhibitors and hypoxic pulmonary vasoconstriction. Respir Physiol Neurobiol 2006; 151: 209-16.
165. Dubuis E, Gautier M, Melin A, Rebocho M, Girardin C, Bonnet P, et al. Chronic carbon monoxide enhanced IbTx-sensitive currents in rat resistance pulmonary artery smooth muscle cells. Am J Physiol Lung Cell Mol Physiol 2002; 283: L120-9.
166. Dubuis E, Potier M, Wang R, Vandier C. Continuous inhalation of carbon monoxide attenuates hypoxic pulmonary hypertension development presumably through activation of BKCa channels. Cardiovasc Res 2005; 65: 751-61.
167. Yun S, Junbao D, Limin G, Chaomei Z, Xiuying T, Chaoshu T. The regulating effect of heme oxygenase/carbon monoxide on hypoxic pulmonary vascular structural remodeling. Biochem Biophys Res Commun 2003; 306: 523-9.
168. Morrell NW, Yang X, Upton PD, Jourdan KB, Morgan N, Sheares KK, et al. Altered growth responses of pulmonary artery smooth muscle cells from patients with primary pulmonary hypertension to transforming growth factor-beta(1) and bone morphogenetic proteins. Circulation 2001; 104: 790-5.
169. Poburko D, Lee CH, van Breemen C. Vascular smooth muscle mitochondria at the cross roads of Ca(2+) regulation. Cell Calcium 2004; 35: 509-21
170. Michelakis ED, Hampl V, Nsair A, Wu X, Harry G, Haromy A, et al. Diversity in mitochondrial function explains differences in vascular oxygen sensing. Circ Res 2002; 90: 1307-15.
171. McMurtry MS, Bonnet S, Wu X, Dyck JR, Haromy A, Hashimoto K. et al. Dichloroacetate prevents and reverses pulmonary hypertension by inducing pulmonary artery smooth muscle cell spoptosis. Circ Res 2004; 95: 830-40.
172. Abenhaim L, Moride Y, Brenot F, Rich S, Benichou J, Kurz Y, et al. Appetite-suppressant drugs and the risk of primary pulmonary hypertension. International Primary Pulmonary Hypertension Study Group. N Engl J Med 1996; 335: 609-16.
173. Weir EK, Reeve HL, Huang JM, Michelakis E, Nelson DP, Hampl V, et al. Anorexic agents aminorex, fenfluramine, and dexfenfluramine inhibit potassium current in rat pulmonary vascular smooth muscle and cause pulmonary vasoconstriction. Circulation 1996; 94: 2216-20.
174. Wang J, Juhaszova M, Conte JV Jr, Gaine SP, Rubin LJ, Yuan JX. Action of fenfluramine on voltage-gated K+ channels in human pulmonary-artery smooth-muscle cells. Lancet 1998; 352:290.
175. Perehenet L, Hilfiger L, Mizrahi J, Clement-Chomienne O. Effects of anorexinogen agents on cloned voltage-gated K(+) channel hKv.1.5. J Pharmacol Exp Ther 2001; 298: 1108-19.
176. Rubin LJ, Badosch DB, Barst RJ, Galie N, Black CM, Keogh A, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2602; 346: 896-903.
177. Humbert, M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med 2004; 351: 1425-36.
178. Aversa A, Bruzziches R, Pili M, Spera, G. Phosphodiesterase 5 inhibitors in the treatment of erectile dysfunction. Curr Pharm Des 2006; 12(27): 3467-84.
179. Reffelmann T, Kloner RA. Cardiovascular effects of phosphodiesterase 5 inhibitors. Curr Pharm Des 2006; 12(27): 3485-94.
180. Yatomi Y. Sphingosine 1-phosphate in vascular biology: Possible therapeutic strategies to control vascular diseases. Curr Pharm Des 2006; 12(5): 575-87.